Imugene (ASX: IMU) invited to present at the coveted J.P. Morgan Healthcare Conference

Highlights

• Imugene has been invited to present at one of the biggest and most reputed conferences, the "41st Annual J.P. Morgan Healthcare Conference"
• Recently, the company presented data on the Phase I CHECKVacc trial at the 2022 San Antonio Breast Cancer Symposium (SABC 2022)
• Earlier this month, Imugene announced the dosing of the first patient in its Phase 1 MAST (metastatic advanced solid tumours) study

Imugene Limited (ASX: IMU) will present at one of the healthcare and biotechnology industries’ biggest and most reputed events, the J.P. Morgan Healthcare Conference.   

The clinical-stage immuno-oncology firm will present at the 41st Annual J.P. Morgan Healthcare Conference, scheduled for 9-12 January 2023 at The Westin St. Francis, San Francisco, California, USA. The 2022 conference saw over 3,000 global investors in attendance.

Imugene is developing a variety of new and novel immunotherapies. It seeks to activate the immune system of cancer patients to treat and eradicate tumours. The company's product pipeline includes multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33). These are targeted at curing several types of cancer in combination with standard-of-care drugs and emerging immunotherapies such as CAR T for solid tumours.

Imugene's CEO Leslie Chong will present at 9:30 am Pacific time on Wednesday, 11 January 2023 (4:30 am AEDT, Thursday, 12 January 2023). Click here to listen to the audio-only broadcast.

© 2022 Kalkine Media®, Data and image source: Company update

Presentation on Phase I CHECKVacc trial

Recently, the company presented new and first data in the Phase I CHECKVacc trial on patients with triple-negative breast cancer (TNBC). The data was presented at a poster presentation at the 2022 San Antonio Breast Cancer Symposium, USA. The presentation was titled "Phase I study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple-negative breast cancer".

Update on Phase 1 MAST study

Earlier this month, the company announced the dosing of the first patient in its Phase 1 MAST (metastatic advanced solid tumours) study. The study aimed to assess the safety of the novel cancer-killing virus CF33-hNIS (VAXINIA).

At the time of writing this article, Imugene shares were trading at AU$0.185 apiece.